Cited by 794Sepsis Diagnosis and TreatmentInflammation biomarkers and pathwaysAntibiotics Pharmacokinetics and Efficacy

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Fisher, Charles J.·1994·JAMA

DOI 10.1001/jama.1994.03510470040032

Open this paper in CoChat — free account

Abstract

Objective. —To further define the safety and efficacy of recombinant human interleukin 1 receptor antagonist (rhIL-1ra) in the treatment of sepsis syndrome. Study Design. —Randomized, double-blind, placebo-controlled, multicenter, multinational clinical trial. Population. —A total of 893 patients with sepsis syndrome received an intravenous loading dose of rhIL-1ra, 100 mg, or placebo followed by a continuous 72-hour intravenous infusion of rhIL-1ra (1.0 or 2.0 mg/kg per hour) or placebo. Outcome Measure. —Twenty-eight—day all-cause mortality. Results. —There was not a significant increase in survival time for rhIL-1ra treatment compared with placebo among all patients who received the study medication (n=893; generalized Wilcoxon statistic,P=.22) or among patients with shock at study entry (n=713; generalized Wilcoxon statistic,P=.23), the two primary efficacy analyses specified a priori for this trial. Results from secondary analyses suggest an increase in survival time with rhIL-1ra treatment among patients with dysfunction of one or more organs (n=563; linear dose-response,P=.009). Retrospective analysis demonstrated an increase in survival time with rhIL-1ra treatment among patients with a predicted risk of mortality of 24% or greater (n=580; linear dose-response,P=.005) as well as among patients with both dysfunction of one or more organs and a predicted risk of mortality of 24% or greater (n=411; linear dose-response,P=.002). Conclusions. —There was not a statistically significant increase in survivial time for rhIL-1ra treatment compared with placebo among all patients who received the study medication or among patients with shock at study entry. Secondary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater. (JAMA. 1994;271:1836-1843)

Integrity signals

Registry

Crossref · 10.1001/jama.1994.03510470040032

Cites

0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The publisher hasn’t deposited this paper’s reference list.

Sorted by citations

Items 201–300 of 794

Efficacy of Topical Blockade of Interleukin-1 in Experimental Dry Eye Disease
Okanobo, A., Chauhan, S. K., Dastjerdi, M. H., Kodati, S., & Dana, R. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.01.034 · Cited by 86
Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm
Narain, S., Stefanov, D. G., Chau, A. S., Weber, A. G., Marder, G. S., Kaplan, B. M., Malhotra, P., Bloom, O., Liu, A., LESSER, M. L., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.09.275 · Cited by 84
Recent advances in the biology of IL-1 family cytokines and their potential roles in development of sepsis
Ge, Y., Huang, M., & Yao, Y.-M. (2018) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2018.12.004 · Cited by 86
Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases
Hallegua, D. S., & Weisman, M. H. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.11.960 · Cited by 84
Immunomodulation in the critically ill
Webster, N. R., & Galley, H. F. (2009) · British Journal of Anaesthesia · doi:10.1093/bja/aep128 · Cited by 85
Phase II multicenter clinical study of the platelet-activating factor receptor antagonist BB-882 in the treatment of sepsis
Vincent, J., Spapen, H. D., Bakker, J., Webster, N. R., & Curtis, L. D. (2000) · Critical Care Medicine · doi:10.1097/00003246-200003000-00006 · Cited by 82
A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia
Bunnell, E., Lynn, M., Habet, K. J., et al. (2000) · Critical Care Medicine · doi:10.1097/00003246-200008000-00005 · Cited by 83
The End of “One Size Fits All” Sepsis Therapies: Toward an Individualized Approach
Vincent, J., van der Poll, T., & Marshall, J. C. (2022) · Biomedicines · doi:10.3390/biomedicines10092260 · Cited by 85
“Anti-IL-1 (IL-1ra) [6,27] TFPI/antithrombin [28–30]”
Blocking Interleukin-1 as a Novel Therapeutic Strategy for Secondary Prevention of Cardiovascular Events
Abbate, A., Tassell, B. W. V., & Biondi‐Zoccai, G. (2012) · BioDrugs · doi:10.1007/bf03261881 · Cited by 78
Randomized, controlled clinical trials in sepsis: Has methodological quality improved over time?
Graf, J., Doig, G., Cook, D., Vincent, J., & Sibbald, W. (2002) · Critical Care Medicine · doi:10.1097/00003246-200202000-00032 · Cited by 73
A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock
Sigalov, A. B. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.05.001 · Cited by 77
Inhalation Injury Severity and Systemic Immune Perturbations in Burned Adults
Davis, C. S., Janus, S. E., Mosier, M. M., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318275f424 · Cited by 76
Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality
Remick, D. G., Call, D. R., Ebong, S., Newcomb, D. E., Nybom, P., Nemzek, J. A., & Bolgos, G. L. (2001) · Critical Care Medicine · doi:10.1097/00003246-200103000-00001 · Cited by 76
A nanotrap improves survival in severe sepsis by attenuating hyperinflammation
Shi, C., Wang, X., Wang, L., Meng, Q., Guo, D., Chen, L., Dai, M. S., Wang, G., Cooney, R. N., & Luo, J. (2020) · Nature Communications · doi:10.1038/s41467-020-17153-0 · Cited by 75
Human macrophage and dendritic cell-specific silencing of high-mobility group protein B1 ameliorates sepsis in a humanized mouse model
Ye, C., Choi, J., Abraham, S., Wu, H., Diaz, D., Terreros, D. A., Shankar, P., & Manjunath, N. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216195109 · Cited by 76
Cytokine Networks with Infection: Mycobacterial Infections, Leishmaniasis, Human Immunodeficiency Virus Infection, and Sepsis
DiPiro, J. T. (1997) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03702.x · Cited by 75
ADVANCES IN THE THERAPY FOR SEPSIS IN CHILDREN
Anderson, M. R., & Blumer, J. L. (1997) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(05)70469-7 · Cited by 74
Leukocyte recruitment in the brain in sepsis: involvement of the annexin 1‐FPR2/ALX anti‐inflammatory system
Gavins, F. N. E., Hughes, E. L., Buss, N. A. P. S., Holloway, P. M., Getting, S. J., & Buckingham, J. C. (2012) · The FASEB Journal · doi:10.1096/fj.12-205971 · Cited by 73
Protection against Lipopolysaccharide-Induced Death by Fluoroquinolones
Khan, A. A., Slifer, T. R., Araujo, F. G., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.11.3169-3173.2000 · Cited by 74
Insulin attenuates endotoxin-induced acute lung injury in conscious rats
Chen, H. I., Yeh, D. Y.-W., Liou, H., & Kao, S. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000201902.37115.22 · Cited by 72
“(40) obtained successful results in the treatment of septic patients with interleukin-1 receptor antagonist.”
Result
Higher-dose Anakinra Is Effective in a Case of Medically Refractory Macrophage Activation Syndrome
Kahn, P. J., & Cron, R. Q. (2013) · The Journal of Rheumatology · doi:10.3899/jrheum.121098 · Cited by 72
Is cytokine removal by continuous hemofiltration feasible?
Sieberth, H., & Kierdorf, H. P. (1999) · Kidney International · doi:10.1046/j.1523-1755.56.s72.14.x · Cited by 72
Mammalian cell death proteases: A family of highly conserved aspartate specific cysteine proteases
Alnemri, E. S. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(199701)64:1 · Cited by 307
Evasion of inflammasome activation by microbial pathogens
Ulland, T. K., Ferguson, P. J., & Sutterwala, F. S. (2015) · Journal of Clinical Investigation · doi:10.1172/jci75254 · Cited by 71
LPS Induces HMGB1 Relocation and Release by Activating the NF-κB-CBP Signal Transduction Pathway in the Murine Macrophage-Like Cell Line RAW264.7
Wu, C., Sun, H., Liu, Q., Guo, H., & Gong, J. (2011) · Journal of Surgical Research · doi:10.1016/j.jss.2011.02.026 · Cited by 70
Crisis in Infectious Diseases: Time for a New Paradigm?
Casadevall, A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.4.790 · Cited by 70
Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis*
Heuer, J. G., Sharma, G. R., Gerlitz, B., et al. (2004) · Critical Care Medicine · doi:10.1097/01.ccm.0000129488.54282.1a · Cited by 69
Serum levels of osteopontin are increased in SIRS and sepsis
Vaschetto, R., Nicola, S., Olivieri, C., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-008-1268-4 · Cited by 68
Interleukin-1 blockade for the treatment of pericarditis
Buckley, L. F., Viscusi, M. M., Tassell, B. W. V., & Abbate, A. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvx018 · Cited by 69
Sepsis research
Nasraway, S. A. (1999) · Critical Care Medicine · doi:10.1097/00003246-199902000-00054 · Cited by 68
Soluble Cytokine Receptors and Receptor Antagonists Are Sequentially Released after Trauma
Cinat, M. E., Waxman, K., Vaziri, N. D., Daughters, K., Yousefi, S., Scannell, G., & Tominaga, G. T. (1995) · doi:10.1097/00005373-199507000-00015 · Cited by 67
Review: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed
Dinarello, C. A. (2004) · Journal of Endotoxin Research · doi:10.1177/09680519040100040301 · Cited by 67
Early Biomarker Activity in Severe Sepsis and Septic Shock and a Contemporary Review of Immunotherapy Trials
Rivers, E. P., Jaehne, A. K., Nguyen, H. B., Papamatheakis, D. G., Singer, D., Yang, J. J., Brown, S., & Klausner, H. (2013) · Shock · doi:10.1097/shk.0b013e31827dafa7 · Cited by 66
Trauma and the immune response
Smith, R. M., & Giannoudis, P. V. (1998) · Journal of the Royal Society of Medicine · doi:10.1177/014107689809100805 · Cited by 67
Correction of perioperative hypothermia decreases experimental sepsis mortality by modulating the inflammatory response
Xiao, H., & Remick, D. G. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000151049.19253.54 · Cited by 66
The Agonists of Formyl Peptide Receptors Prevent Development of Severe Sepsis after Microbial Infection
Kim, S. D., Kim, Y., Lee, H. Y., Kim, Y.-S., Jeon, S. G., Baek, S., Song, D., Ryu, S. H., & Bae, Y. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001310 · Cited by 65
“, platelet-activating factor antagonist (36), rIL-1 receptor antagonist (37, 38), genetically engineered soluble receptors for TNF-a, and mAbs to TNF-a (39)]—have not prevented the death of patients with severe sepsis or septic shock (34).”
Background
Sepsis: State of the art
Marik, P. E., & Varón, J. (2001) · Disease-a-Month · doi:10.1067/mda.2001.119745 · Cited by 62
Endogenous mediators in emergency department patients with presumed sepsis: Are levels associated with progression to severe sepsis and death?
Terregino, C. A., Lopez, B. L., Karras, D. J., Killian, A. J., & Arnold, G. K. (2000) · Annals of Emergency Medicine · doi:10.1016/s0196-0644(00)70101-6 · Cited by 64
Inner sensors of endotoxin – implications for sepsis research and therapy
Skirecki, T., & Cavaillon, J. (2019) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuz004 · Cited by 64
Intravenous administration of anakinra in children with macrophage activation syndrome
Phadke, O., Rouster‐Stevens, K. A., Giannopoulos, H. T., Chandrakasan, S., & Prahalad, S. (2021) · Pediatric Rheumatology · doi:10.1186/s12969-021-00585-3 · Cited by 63
“In both these instances no excess adverse effects or microbial superinfections were attributed to the IL-1 inhibitor [14, 15].”
BackgroundResult
Barriers to the effective treatment of sepsis: antimicrobial agents, sepsis definitions, and host‐directed therapies
Lyle, N. H., Pena, O. M., Boyd, J. H., & Hancock, R. E. W. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12444 · Cited by 63
Acute Neurodegeneration and the Inflammasome: Central Processor for Danger Signals and the Inflammatory Response?
Trendelenburg, G. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600609 · Cited by 64
“…episodes of fever, skin rashes, and tissue inflammation, and there is a possibility that they might be treated with the IL-1 antagonist anakinra (Fisher et al, 1994; Liao et al, 1984; Dinarello, 2005; Braddock and Quinn, 2004; Goldbach-Mansky et al, 2006; Hawkins et al, 2004; Hoffman et al,…”
Pharmacology of Acute Lung Injury
Tasaka, S., Hasegawa, N., & Ishizaka, A. (2002) · Pulmonary Pharmacology & Therapeutics · doi:10.1006/pupt.2001.0325 · Cited by 63
Functional imaging of interleukin 1 beta expression in inflammatory process using bioluminescence imaging in transgenic mice
Li, L., Fei, Z., Ren, J., et al. (2008) · BMC Immunology · doi:10.1186/1471-2172-9-49 · Cited by 63
New strategies for treatment of infectious sepsis
Ward, P. A., & Fattahi, F. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4mir1118-425r · Cited by 62
Helminths and their implication in sepsis - a new branch of their immunomodulatory behaviour?
Hübner, M. P., Layland, L. E., & Hoerauf, A. M. (2013) · Pathogens and Disease · doi:10.1111/2049-632x.12080 · Cited by 61
“Moreover, in W. bancrofti-infected individuals, this effect was shown to be dependent on the presence of Mf (Arndts et al., 2012), and monocytes from such patients show reduced IL-1b production following LPS stimulation (Sasisekhar et al., 2005).”
BackgroundInfluential
Differences in the repertoire, regulation and function of Toll-like Receptors and inflammasome-forming Nod-like Receptors between human and mouse
Ariffin, J. K., & Sweet, M. J. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.03.002 · Cited by 63
Multicenter evaluation of a human monoclonal antibody to Entero-bacteriaceae common antigen in patients with Gram-negative sepsis
Albertson, T. E., Panacek, E. A., MacArthur, R. D., Johnson, S. B., Benjamin, E., Matuschak, G. M., Zaloga, G. P., Maki, D. G., Silverstein, J. H., Tobias, J. K., et al. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000045564.51812.3f · Cited by 61
Bench-to-bedside review: Sepsis, severe sepsis and septic shock – does the nature of the infecting organism matter?
Gao, H., Evans, T. W., & Finney, S. J. (2008) · Critical Care · doi:10.1186/cc6862 · Cited by 59
Effect of Levocarnitine vs Placebo as an Adjunctive Treatment for Septic Shock
Jones, A. E., Puskarich, M. A., Shapiro, N. I., Guirgis, F. W., Runyon, M. S., Adams, J. Y., Sherwin, R. L., Arnold, R., Roberts, B. W., Kurz, M. C., et al. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6076 · Cited by 60
Management of sepsis in neutropenic patients: guidelines from the infectious diseases working party of the German Society of Hematology and Oncology
Penack, O., Buchheidt, D., Christopeit, M., von Lilienfeld‐Toal, M., Massenkeil, G., Hentrich, M., Salwender, H. J., Wolf, H., & Ostermann, H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq442 · Cited by 61
Procalcitonin and Proinflammatory Cytokine Clearance during Continuous Venovenous Haemofiltration in Septic Patients
Dahaba, A. A., El-Awady, G. A., Rehak, P., et al. (2002) · Anaesthesia and Intensive Care · doi:10.1177/0310057x0203000302 · Cited by 61
Immunomodulatory therapy for sepsis: an update
Christaki, E., Anyfanti, P., & Opal, S. M. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.122 · Cited by 60
Serum Lipopolysaccharide Binding Protein Levels Predict Severity of Lung Injury and Mortality in Patients with Severe Sepsis
Villar, J., Pérez‐Méndez, L., Espinosa, E., Flores, C., Blanco, J., Muriel, A., Basaldúa, S., Muros, M., Blanch, L. L., Artigas, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006818 · Cited by 59
The Problems and Challenges of Immunotherapy in Sepsis
Nasraway, S. A. (2003) · CHEST Journal · doi:10.1378/chest.123.5_suppl.451s · Cited by 60
The 2022 EULAR / ACR Points to Consider at the Early Stages of Diagnosis and Management of Suspected Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome ( HLH / MAS )
Shakoory, B., Geerlinks, A. V., Wilejto, M., Kernan, K. F., Hines, M., Romano, M., Piskin, D., Ravelli, A., Sinha, R. R., Aletaha, D., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42636 · Cited by 60
Pharmacokinetic modelling of interleukin‐1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage
Gueorguieva, I., Clark, S., McMahon, C. J., Scarth, S., Rothwell, N. J., Tyrrell, P. J., Hopkins, S. J., & Rowland, M. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03026.x · Cited by 59
Tight glycemic control may favor fibrinolysis in patients with sepsis*
Savioli, M., Cugno, M., Polli, F., Taccone, P., Bellani, G., Spanu, P., Pesenti, A. M., Iapichino, G., & Gattinoni, L. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819542da · Cited by 58
Gender dimorphism following injury: making the connection from bench to bedside
Sperry, J. L., & Minei, J. P. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0607360 · Cited by 59
“However, clinical trials were unable to reproduce these experimental animal findings [113–118].”
Background
Combined Blockade of Interleukin-1α and -1β Signaling Protects Mice from Cognitive Dysfunction after Traumatic Brain Injury
Newell, E. A., Todd, B. P., Mahoney, J., Pieper, A., Ferguson, P., & Bassuk, A. (2018) · eNeuro · doi:10.1523/eneuro.0385-17.2018 · Cited by 55
“More broadly, the IL-1R blocking drug anakinra is currently FDA-approved for rheumatoid arthritis and has also been studied for off-label use in other disorders with an inflammatory component, including stroke and TBI (Fisher et al., 1994; Emsley et al., 2005; Fleischmann et al., 2006; Helmy et al., 2014; Singh et al.…”
Background
Tamarixetin Exhibits Anti-inflammatory Activity and Prevents Bacterial Sepsis by Increasing IL-10 Production
Park, H. J., Lee, S., Cho, J., Gharbi, A., Han, H. D., Kang, T. H., Kim, Y., Lee, Y., Park, W. S., Jung, I. D., et al. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b00155 · Cited by 58
IMMUNOLOGIC RESPONSE TO INFECTION AND ITS ROLE IN SEPTIC SHOCK
Casey, L. C. (2000) · Critical Care Clinics · doi:10.1016/s0749-0704(05)70107-x · Cited by 58
A Primer in Cytokines
Gosain, A., & Gamelli, R. L. (2005) · Journal of Burn Care & Rehabilitation · doi:10.1097/01.bcr.0000150214.72984.44 · Cited by 59
The Design of Randomized Clinical Trials in Critically Ill Patients
Hébert, P. C., Cook, D. J., Wells, G. A., & Marshall, J. C. (2002) · CHEST Journal · doi:10.1378/chest.121.4.1290 · Cited by 59
Experimental Human Endotoxemia: A Model of the Systemic Inflammatory Response Syndrome?
Calvano, S. E., & Coyle, S. M. (2012) · Surgical Infections · doi:10.1089/sur.2012.155 · Cited by 57
Sepsis Induced by Cecal Ligation and Puncture
Wen, H. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-481-4_15 · Cited by 57
Influence of heat shock protein 70 and metallothionein induction by Zinc-Bis-(DL-Hydrogenaspartate) on the release of inflammatory mediators in a porcine model of recurrent endotoxemia
Klosterhalfen, B., Töns, C., Hauptmann, S., et al. (1996) · Biochemical Pharmacology · doi:10.1016/0006-2952(96)00469-8 · Cited by 57
NQO1 inhibits the TLR-dependent production of selective cytokines by promoting IκB-ζ degradation
Kimura, A., Kitajima, M., Nishida, K., Serada, S., Fujimoto, M., Naka, T., Fujii‐Kuriyama, Y., Sakamato, S., Ito, T., Handa, H., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20172024 · Cited by 58
“Clinical trials based on the neutralization of TNF-α or IL-1β have failed to recover the pathogenesis and survival of patients with sepsis (Fisher et al., 1994; Abraham et al., 1998, 2001).”
Background
International sepsis trial (INTERSEPT)
Sprung, C. L., Finch, R. G., THIJS, L. G., et al. (1996) · Critical Care Medicine · doi:10.1097/00003246-199609000-00003 · Cited by 56
Sepsis, Severe Sepsis, and Septic Shock
Munford, R. S., & Suffredini, A. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-443-06839-3.00070-9 · Cited by 55
Proinflammatory mediator activity, endogenous antagonists and the systemic inflammatory response in intra-abdominal sepsis
Wakefield, C. H., Barclay, G. R., Fearon, K. C. H., Goldie, A. S., Ross, J. A., Grant, I. S., Ramsay, G., & Howie, J. C. (1998) · British journal of surgery · doi:10.1046/j.1365-2168.1998.00710.x · Cited by 55
Management and Cure of Gouty Arthritis
Keller, S. F., & Mandell, B. F. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2020.09.013 · Cited by 54
Serial increase of IL-12 response and human leukocyte antigen-DR expression in severe sepsis survivors
Wu, H.-P., Shih, C.-C., Lin, C., Hua, C., & Chuang, D. (2011) · Critical Care · doi:10.1186/cc10464 · Cited by 55
The neutrophil elastase inhibitor, sivelestat, attenuates sepsis-related kidney injury in rats
Li, G., Jia, J., Ji, K., Gong, X., Wang, R., Zhang, X., Wang, H., & Zang, B. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2665 · Cited by 54
“Although sivelestat alone generated no changes in the serum levels of TNF-α and IL-1 β as compared to the sham-operated group (P>0.05), a marked inhibitory effect of sivelestat on these two pro-inflammatory cytokines in the rats with sepsis rats was observed (Fig.”
Influential
Human genetic and metabolite variation reveals that methylthioadenosine is a prognostic biomarker and an inflammatory regulator in sepsis
Wang, L., Ko, E. R., Gilchrist, J. J., Pittman, K. J., Rautanen, A., Pirinen, M., Thompson, J. W., Dubois, L. G., Langley, R. J., Jaslow, S. L., et al. (2017) · Science Advances · doi:10.1126/sciadv.1602096 · Cited by 52
Chemokine C10 Promotes Disease Resolution and Survival in an Experimental Model of Bacterial Sepsis
Steinhauser, M. L., Hogaboam, C. M., Matsukawa, A., et al. (2000) · Infection and Immunity · doi:10.1128/iai.68.11.6108-6114.2000 · Cited by 54
Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)
Sheng, C. C., Sahoo, D. H., Dugar, S. P., Prada, R. A., Wang, T. K. M., Hassan, O. K. A., Brennan, D. M., Culver, D. A., Rajendram, P., Duggal, A., et al. (2020) · Clinical Cardiology · doi:10.1002/clc.23451 · Cited by 51
Procalcitonin (PCT) is useful in predicting the bacterial origin of an acute circulatory failure in critically ill patients
Cheval, C., Timsit, J., Garrouste-Orgeas, M., et al. (2000) · Intensive Care Medicine · doi:10.1007/bf02900729 · Cited by 52
Sepsis: current status, future prospects
Marshall, J. C. (2004) · Current Opinion in Critical Care · doi:10.1097/01.ccx.0000134877.60312.f3 · Cited by 51
Sepsis reconsidered: Identifying novel metrics for behavioral landscape characterization with a high-performance computing implementation of an agent-based model
Cockrell, C., & An, G. C. (2017) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2017.07.016 · Cited by 50
Short-term and long-term outcome prediction with the Acute Physiology and Chronic Health Evaluation II system after orthotopic liver transplantation
Angus, D. C., Clermont, G., Kramer, D. J., Linde‐Zwirble, W. T., & Pinsky, M. R. (2000) · Critical Care Medicine · doi:10.1097/00003246-200001000-00025 · Cited by 50
“patients, often considered different from other general medical and surgical ICU patients, and usually excluded from randomized trials in the ICU (33-35).”
Background
New Therapies in Sepsis
Vincent, J. (1997) · CHEST Journal · doi:10.1378/chest.112.6_supplement.330s · Cited by 51
Maternal Death Following Cardiopulmonary Collapse After Delivery: Amniotic Fluid Embolism or Septic Shock Due to Intrauterine Infection?
Romero, R. J., Kadar, N. R., Vaisbuch, E., & Hassan, S. S. (2010) · American Journal of Reproductive Immunology · doi:10.1111/j.1600-0897.2010.00823.x · Cited by 48
Apheresis as Therapy for Patients with Severe Sepsis and Multiorgan Dysfunction Syndrome
Stegmayr, B. G. (2001) · Therapeutic Apheresis and Dialysis · doi:10.1046/j.1526-0968.2001.005002123.x · Cited by 50
Advances in Sepsis Therapy
Gl�ck, T., & Opal, S. M. (2004) · Drugs · doi:10.2165/00003495-200464080-00004 · Cited by 50
UROSEPSIS IN THE CRITICAL CARE UNIT
Paradisi, F., Corti, G., & Mangani, V. (1998) · Critical Care Clinics · doi:10.1016/s0749-0704(05)70390-0 · Cited by 50
A Functional Synonymous Coding Variant in the IL1RN Gene Is Associated with Survival in Septic Shock
Meyer, N. J., Ferguson, J. F., Feng, R., Wang, F., Patel, P. N., Li, M., Xue, C., Qu, L., Liu, Y., Boyd, J. H., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0586oc · Cited by 52
Wnt5A/Ryk signaling critically affects barrier function in human vascular endothelial cells
Skaria, T., Bächli, E., & Schoedon, G. (2016) · Cell Adhesion & Migration · doi:10.1080/19336918.2016.1178449 · Cited by 49
HMGB1/IL-1β complexes in plasma microvesicles modulate immune responses to burn injury
Coleman, L. G., Maile, R., Jones, S., Cairns, B. A., & Crews, F. T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195335 · Cited by 50
Sepsis in Burns
Chipp, E., Milner, C. S., & Blackburn, A. (2010) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e3181c9c35c · Cited by 48
“This is in part due to the great complexity of the multiple signaling mechanisms in inflammation, its close interdependence with coagulation, and its ability to evade pharmacologic efforts to block certain key pathways such as IL-1 or TNFmessaging.(99,100) It is therefore likely that new drug treatments will need to t…”
Background
Hematopoietic Stem-Progenitor Cells Restore Immunoreactivity and Improve Survival in Late Sepsis
Brudecki, L. E., Ferguson, D. A., Yin, D., LeSage, G., McCall, C. E., & Gazzar, M. E. (2011) · Infection and Immunity · doi:10.1128/iai.05480-11 · Cited by 48
Cardiovascular dysfunction in sepsis at the dawn of emerging mediators
Sergi, C. M., Shen, F., Lim, D. W., Liu, W., Zhang, M.-Y., Chiu, B., Anand, V., & Sun, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.066 · Cited by 48
Thymosin alpha 1 treatment for patients with sepsis
Pei, F., Guan, X., & Wu, J. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1484104 · Cited by 49
Targeting cytokines to treat autoinflammatory diseases
Hausmann, J. S. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.10.016 · Cited by 48
Anti-Cytokine Therapies in Response to Systemic Infection
Dinarello, C. A. (2001) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1046/j.0022-202x.2001.00046.x · Cited by 47
1995 Jonathan E. Rhoads Lecture. The Nutrition Management of the Patient With Acute Renal Failure
Kopple, J. D. (1996) · Journal of Parenteral and Enteral Nutrition · doi:10.1177/014860719602000103 · Cited by 48
Role for Anti-Cytokine Therapies in Severe Coronavirus Disease 2019
Buckley, L. F., Wohlford, G. F., Ting, C., Alahmed, A. A., Tassell, B. W. V., Abbate, A., Devlin, J. W., & Libby, P. (2020) · Critical Care Explorations · doi:10.1097/cce.0000000000000178 · Cited by 48
Mechanisms and modulation of sepsis-induced immune dysfunction in children
Mithal, L. B., Arshad, M., Swigart, L. R., Khanolkar, A., Ahmed, A. S., & Coates, B. M. (2021) · Pediatric Research · doi:10.1038/s41390-021-01879-8 · Cited by 50
Anti-endotoxin vaccines
Cross, A. S. (2013) · Virulence · doi:10.4161/viru.25965 · Cited by 47
Vascular cell adhesion molecule–1 expression is obligatory for endotoxin-induced myocardial neutrophil accumulation and contractile dysfunction
Raeburn, C. D., Calkins, C. M., Zimmerman, M. A., Song, Y., Ao, L., Banerjee, A. M., Meng, X., & Harken, A. H. (2001) · Surgery · doi:10.1067/msy.2001.116410 · Cited by 45

Authors: Fisher, C. J.
Corresponding author: Fisher, Charles J.
ORCID: Fisher, Charles J.
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 1994-06-15
Volume: 271
Issue: 23
Pages: 1836
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.1994.03510470040032
OpenAlex: W4322697531
Cited by: 790
References: 0
Citations by year: 2026: 11 · 2025: 23 · 2024: 18 · 2023: 28 · 2022: 15 · 2021: 18 · 2020: 32 · 2019: 23 · 2018: 24 · 2017: 22 · 2016: 19 · 2015: 18 · 2014: 30 · 2013: 20 · 2012: 22
FWCI: 37.99
Type: journal article
Language: en
Open access: closed
Locations: JAMA (publishedVersion)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Keywords: sepsis, septic shock, survival, organ dysfunction, mortality risk, dose-response relationship, drug safety, cytokine inhibition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks